Literature DB >> 2958545

Antigen-induced human interferon-gamma production. Differential dependence on interleukin 2 and its receptor.

C D Kelly1, K Welte, H W Murray.   

Abstract

Once stimulated with Toxoplasma gondii or cytomegalovirus (CMV) antigens, peripheral blood mononuclear cells from healthy seropositive donors secrete comparable levels of interferon-gamma (IFN-gamma). Both antigens also stimulated specific production of interleukin 2 (IL-2), a lymphokine believed to be important in IFN-gamma generation. T. gondii antigen, however, induced ninefold more IL-2 than did CMV antigen suggesting different mechanisms for antigen-stimulated IFN-gamma production. Therefore, we examined for both antigens 1) the cellular sources of IL-2 and IFN-gamma, 2) the kinetics of IL-2 production and IL-2 receptor (IL-2R) expression, and 3) the effect of antibodies to IL-2 and IL-2R on IFN-gamma secretion. For both antigens, IL-2 and IFN-gamma secretion was T4+ cell-dependent. T. gondii antigen induced high levels of IL-2 at 24 hr which increased further at 48 hr, and IFN-gamma production was strongly inhibited by antibodies to both IL-2 (90 +/- 2%) and IL-2R (80 +/- 5%). In contrast, CMV antigen stimulated low levels of IL-2 at 24 hr which declined still further by 48 hr, and CMV-stimulated IFN-gamma generation was appreciably less well inhibited by antibodies to IL-2 (47 +/- 2%) and IL-2R (31 +/- 8%). These results suggest the possibility of two mechanisms for antigen-induced IFN-gamma production--one primarily dependent on and the other largely independent of IL-2 and its receptor. Both mechanisms, however, require the activity of sensitized T4+ cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2958545

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Purification of a factor which provides a costimulatory signal for gamma interferon production.

Authors:  K Nakamura; H Okamura; K Nagata; T Komatsu; T Tamura
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

2.  Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis.

Authors:  H W Murray; M J Oca; A M Granger; R D Schreiber
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

3.  Antigen-stimulated human interferon-gamma generation: role of accessory cells and their expressed or secreted products.

Authors:  C D Kelly; C M Russo; B Y Rubin; H W Murray
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

4.  Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro.

Authors:  A Thanhäuser; A Böhle; H D Flad; M Ernst; T Mattern; A J Ulmer
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

Review 5.  Role of gamma interferon in Toxoplasma gondii infection.

Authors:  C S Subauste; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

6.  In vitro production of interferon-gamma by peripheral blood from patients with Graves' disease, Hashimoto's thyroiditis and rheumatoid arthritis.

Authors:  S Matsubayashi; F Akasu; Y Kasuga; K Snow; E Keystone; R Volpé
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

Review 7.  Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.

Authors:  Alti Dayakar; Sambamurthy Chandrasekaran; Suresh V Kuchipudi; Suresh K Kalangi
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

8.  Toxoplasma gondii infection and peripheral-blood gene expression profiling of older people reveals dysregulation of cytokines and identifies hub genes as potential therapeutic targets.

Authors:  Carlos A Naranjo-Galvis; Kelly Y Cardona-Londoño; Mary Orrego-Cardozo; Xabier Elcoroaristizabal-Martín
Journal:  Heliyon       Date:  2022-09-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.